title: Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn.
abstract: OBJECTIVE
  To evaluate whether the use of intravenous immunoglobulin in newborn infants with isoimmune hemolytic jaundice due to Rh and ABO incompatibility is an effective treatment in reducing the need for exchange transfusion.
  
  
  METHODS
  This study included all direct Coombs' test positive Rh and ABO isoimmunized babies, who admitted in the Neonatal Intensive Care Unit of Ghaem Hospital of Mashhad University of Medical Sciences, Iran, from October 2003 to October 2004. Significant hyperbilirubinemia was defined as rising by >or=0.5 mg/dl per hour. Babies were randomly assigned to received phototherapy with intravenous immunoglobulin (IVIg) 0.5 g/kg over 4 hours, every 12 hours for 3 doses (study group) or phototherapy alone (control group). Exchange transfusion was performed in any group if serum bilirubin exceeded >or=20mg/dl or rose by >or=1mg/dl/h.
  
  
  RESULTS
  A total of 34 babies were eligible for this study (17 babies in each group). The number of exchange transfusion, duration of phototherapy and hospitalization days, were significant shorter in the study group versus control group. When we analyzed the outcome results in ABO and Rh hemolytic disease separately, the efficacy of IVIg was significantly better in Rh versus ABO isoimmunization. Late anemia was more common in the IVIg group 11.8% versus 0%, p=0.48. Adverse effects were not observed during IVIg administration.
  
  
  CONCLUSIONS
  Administration of IVIg to newborns with significant hyperbilirubinemia due to Rh hemolytic disease reduced the need for exchange transfusion but in ABO hemolytic disease there was no significant difference between IVIg and double surface blue light phototherapy.
authors.affiliation: Division of Neonatology, Department of Pediatrics, Mashhad University of Medical Sciences, Iran. nasseri@med.mui.ac.ir
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Nasseri
authors.forename: Gholam A
authors.initials: GA
authors.lastname: Mamouri
authors.forename: Homa
authors.initials: H
authors.lastname: Babaei
mesh_terms: D000017:ABO Blood-Group System; D004899:Erythroblastosis, Fetal / Q000188:drug therapy*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007231:Infant, Newborn; D008297:Male; D012203:Rh Isoimmunization / Q000188:drug therapy*
chemical_list: D000017:ABO Blood-Group System; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors